Apogee Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 261

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $10.1B

Apogee Therapeutics General Information

Description

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 221 Crescent Street
  • Waltham, MA 02453
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Vertical(s)
Corporate Office
  • 221 Crescent Street
  • Waltham, MA 02453
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apogee Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 03-Sep-2026 $10.1B Completed Generating Revenue
8. General Corporate Purpose 27-May-2026 Completed Generating Revenue
7. 2PO 24-Mar-2026 Completed Generating Revenue
6. 2PO 10-Oct-2025 Completed Generating Revenue
5. 2PO 11-Mar-2024 Completed Generating Revenue
4. IPO 13-Jul-2023 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 07-Dec-2022 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Jun-2022 $20M $20M Completed Pre-Clinical Trials
1. Spin-Off 01-Jan-2022 Completed Pre-Clinical Trials
To view Apogee Therapeutics’s complete valuation and funding history, request access »

Apogee Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with t
Biotechnology
Waltham, MA
261 As of 2025

San Diego, CA
 

Newton, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apogee Therapeutics Competitors (66)

One of Apogee Therapeutics’s 66 competitors is Sorrento Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Adiso Therapeutics Venture Capital-Backed Newton, MA
Innovimmune Biotherapeutics Accelerator/Incubator Backed New York, NY
Minerva Neurosciences Formerly VC-backed Burlington, MA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 66 competitors. Get the full list »

Apogee Therapeutics Patents

Apogee Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213500-A1 Dosage and administration of ox40l antibodies in combination with il-13 antibodies Pending 04-Apr-2025
WO-2026151705-A1 Dosage and administration of interleukin-13 antibody to treat asthma Pending 07-Jan-2025
WO-2026151705-A9 Dosage and administration of interleukin-13 antibody to treat asthma Pending 07-Jan-2025
WO-2026112477-A1 Co-formulation of ox40l antibodies and il-13 antibodies Pending 22-Nov-2024
WO-2026112418-A2 Ox40l antibody formulation Pending 22-Nov-2024 A61K39/39591
To view Apogee Therapeutics’s complete patent history, request access »

Apogee Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apogee Therapeutics Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Access Biotechnology Corporate Venture Capital Minority
Deep Track Capital Venture Capital Minority
Fairmount Partners Investment Bank Minority
Fidelity Management & Research Company Asset Manager Minority
OrbiMed Growth/Expansion Minority
You’re viewing 5 of 12 investors. Get the full list »

Apogee Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

36.28 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Apogee Therapeutics’s complete esg history, request access »

Apogee Therapeutics FAQs

  • When was Apogee Therapeutics founded?

    Apogee Therapeutics was founded in 2022.

  • Where is Apogee Therapeutics headquartered?

    Apogee Therapeutics is headquartered in Waltham, MA.

  • What is the size of Apogee Therapeutics?

    Apogee Therapeutics has 261 total employees.

  • What industry is Apogee Therapeutics in?

    Apogee Therapeutics’s primary industry is Biotechnology.

  • Is Apogee Therapeutics a private or public company?

    Apogee Therapeutics is a Private company.

  • What is the current valuation of Apogee Therapeutics?

    The current valuation of Apogee Therapeutics is .

  • What is Apogee Therapeutics’s current revenue?

    The current revenue for Apogee Therapeutics is .

  • How much funding has Apogee Therapeutics raised over time?

    Apogee Therapeutics has raised $2.12B.

  • Who are Apogee Therapeutics’s investors?

    Access Biotechnology, Deep Track Capital, Fairmount Partners, Fidelity Management & Research Company, and OrbiMed are 5 of 12 investors who have invested in Apogee Therapeutics.

  • Who are Apogee Therapeutics’s competitors?

    Sorrento Therapeutics, Adiso Therapeutics, Innovimmune Biotherapeutics, Minerva Neurosciences, and Sarepta Therapeutics are some of the 66 competitors of Apogee Therapeutics.

  • When was Apogee Therapeutics acquired?

    Apogee Therapeutics was acquired on 03-Sep-2026.

  • Who acquired Apogee Therapeutics?

    Apogee Therapeutics was acquired by AbbVie.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process